Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -144973.96% is 1499% below its 3-year average of -9066.23%, near the low end of its 3-year range (-144973.96%–-22.76%).
614.78% below its 12-month average of -20282.43%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2018 (2018-03-31): -45712.33%.
EBITDA MARGIN
-144973.96%
EBITDA MARGIN AVG TTM
-20282.43%
EBITDA MARGIN AVG 3Y
-9066.23%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-614.78%
CURRENT VS 3Y AVG
-1499.05%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ENDRA Life Sciences Inc.
Market Cap
$7.67M
EBITDA Margin
-144973.96%
TTM Avg
-20282.43%
3Y Avg
-9066.23%
5Y Avg
N/A
Market Cap
$7.64M
EBITDA Margin
-3822.36%
TTM Avg
-2499.82%
3Y Avg
-7123.25%
5Y Avg
-7123.25%
Market Cap
$7.87M
EBITDA Margin
-951.52%
TTM Avg
-1801.56%
3Y Avg
-1801.56%
5Y Avg
-1801.56%
Market Cap
$7.92M
EBITDA Margin
-638.49%
TTM Avg
-11234.29%
3Y Avg
-10030.31%
5Y Avg
-9704.67%
Market Cap
$7.31M
EBITDA Margin
-0.29%
TTM Avg
-74.83%
3Y Avg
-125.41%
5Y Avg
-344.12%
Market Cap
$8.04M
EBITDA Margin
-33055.56%
TTM Avg
-18473.68%
3Y Avg
-9547.23%
5Y Avg
-12604.39%
Market Cap
$8.05M
EBITDA Margin
-334.15%
TTM Avg
-180.95%
3Y Avg
-121.99%
5Y Avg
-121.99%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ENDRA Life Sciences Inc. (NDRA) | $7.67M | -144973.96% | -20282.43% | -9066.23% | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.64M | -3822.36% | -2499.82% | -7123.25% | -7123.25% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | N/A | N/A | N/A | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.87M | -951.52% | -1801.56% | -1801.56% | -1801.56% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.46M | N/A | N/A | N/A | N/A |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | -638.49% | -11234.29% | -10030.31% | -9704.67% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -0.29% | -74.83% | -125.41% | -344.12% |
| GT Biopharma, Inc. (GTBP)vs › | $8.04M | -33055.56% | -18473.68% | -9547.23% | -12604.39% |
| DataMEDS AI, Inc. (MEDS)vs › | $8.05M | -334.15% | -180.95% | -121.99% | -121.99% |
| HeartSciences Inc. (HSCS)vs › | $8.14M | -194787.38% | -191929.49% | -133856.30% | -96317.48% |
Gross Margin
0.0%
EBITDA Margin
-144974.0%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2018-03-31 | -45712.33% |
| 2017-12-31 | -33302.35% |
| 2017-09-30 | -312.12% |
| 2017-06-30 | -1802.92% |
| 2016-12-31 | -58.29% |
| 2015-12-31 | -172.17% |
| 2015-09-30 | -167.12% |
| 2015-06-30 | -22.76% |
| 2015-03-31 | -46.06% |
